Furthermore, Ji et al (86) developed a miR26-diagnostic test, which may assist in the selection of candidate HCC patients who exhibit a favorable overall survival response to adjuvant IFN-α treatment. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.